News
News of Sino Biopharm
-
- 03
- 2022/09
"CTTQ", 4 Big Characters Shine on the Hope School's Teaching Building
On September 2, the first phase of the construction of Anhui Linquan Medical Hope School, which was supported by CTTQ, Chiatai Tianqing, was completed. Zhai Qi, deputy governor of Linquan County; Shui Dong, deputy director of Linquan Education Bureau; Zhang Dahong, principal of Chengdong Street Central School; Zhang Kui, principal of Linquan Medical Hope School and Zhuang Xinglong, vice president of CTTQ attended the completion ceremony.View > -
- 28
- 2022/08
Secretary of Shanghai Municipal Party Committee Li Qiang Meets with CEO of Sino Biopharm Mr. Tse, Eric S Y
On the morning of August 27, Li Qiang, Secretary of Shanghai Municipal Party Committee, met with the representatives of the 3rd Shanghai Innovation and Entrepreneurship Youth 50 Forum. Mr. Tse, Eric S Y, CEO of Sino Biopharm, attended the meeting as a representative of the Youth 50 Forum.View > -
- 27
- 2022/08
Sino Biopharm CEO Mr. Tse, Eric S Y Was Awarded the Title of "Top Ten Outstanding Youths of Lianyungang"
On August 26, the 13th "Top Ten Outstanding Youths of Lianyungang" jointly organized by the Organization Department, Propaganda Department and United Front Work Department of Lianyungang Municipal Committee, Communist Youth League, Municipal Newspaper and Media Group, Municipal Radio and Television Media Group, and Municipal Youth Federation was selected.View > -
- 25
- 2022/08
Sino Biopharm Holds 2022 Interim Results Announcement and First Investor Day
On the morning of August 24, Sino Biopharm (HK.01177) held its 2022 interim results conference and the first Investor Day in Beijing. The company's Chairwoman of the Board of Directors, Miss Tse, Theresa Y Y, the new Chief Executive Officer (CEO), Mr. Tse, Eric S Y, and the company's senior management attended the event, which was also participated by investors and media from around the world through offline and online means.View > -
- 15
- 2022/08
Shaanxi Provincial Party Secretary Liu Guozhong Meets with CP Pharmaceutical President Cheng Cheung Ling
On the evening of August 14, Shaanxi Provincial Party Secretary Liu Guozhong met with President of CP Pharmaceutical Group and the General Association of Shaanxi Entrepreneurs Cheng Cheung Ling and her entourage, and had a discussion with the representatives attending the 12th Global Qin Business Conference.View > -
- 09
- 2022/08
CTTQ of Sino Biopharm's Anlotinib Compound Patent Wins China Patent Gold Award
Recently, China National Intellectual Property Administration announced the decision of the 23rd China Patent Award, and the compound patent of Anlotinib, a new class 1 drug in the field of anti-tumor of Sino Biopharm CTTQ, "Spiro-substituted compounds as angiogenesis inhibitors"(Patent No. ZL200880007358.X), won the "China Patent Gold Award"View > -
- 05
- 2022/08
Nanjing Chia Tai Tianqing of Sino Biopharm Wins 2022 Nanjing Excellent Patent Award
Recently, Nanjing Intellectual Property Office issued the "Decision on the Recognition of 2022 Nanjing Excellent Patent Award (Ning Zhi [2022] No. 25)", in which Nanjing Chia Tai Tianqing, a subsidiary of Sino Biopharm, won the Nanjing Excellent Patent Award for its invention patent "a method of preparing idarubicin hydrochloride".View > -
- 03
- 2022/08
Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group and Chairwoman of Beijing Tide Pharmaceutical, Was Awarded "Top 10 Figures in Pharmaceutical Industry"
On August 3, 2022, the 14th China Health Forum - Top 10 Figures in Pharmaceutical Industry list release ceremony was held. Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group, Vice Chairwoman of the Board of Directors of Sino Biopharm, and Chairwoman of the Board of Directors of Beijing Tide Pharmaceutical Co.View > -
- 21
- 2021/12
Innovative Medicine "TCR1672" obtained Approval for Clinical Trial
Recently, “TCR1672”, a second-generation, highly selective P2X3 receptor antagonist self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration of China to commence clinical trial for refractory chronic cough (RCC) in China.View > -
- 20
- 2021/12
Exclusive Sales Agreement of Penpulimab Monoclonal Antibody
Dec 20, Sino Biopharm announces that the Group has entered into an exclusive sales agreement of Penpulimab monoclonal antibody with its associate CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. and the associate’s shareholder Akeso Biopharma Co., Ltd.View >